Clinical Report: Utilization of Glucocorticoids for Severe Myelosuppression

Overview

This report discusses two lung cancer patients who experienced significant myelosuppression following immune checkpoint inhibitor and chemotherapy combination therapy. Both patients achieved full hematologic restoration with high-dose glucocorticoids, highlighting the importance of timely intervention in such cases.

Background

Myelosuppression is a common adverse effect of chemotherapy, often leading to severe complications and treatment delays. The combination of immune checkpoint inhibitors (ICIs) with chemotherapy may exacerbate myelosuppression, yet this phenomenon is not well-documented. Understanding the mechanisms and management strategies for ICI-related myelosuppression is crucial for improving patient outcomes.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

• Both patients experienced grade IV myelosuppression and pancytopenia following ICI and chemotherapy.
• Immune-mediated myelosuppression was identified through exclusion of alternative causes.
• High-dose glucocorticoids led to full hematologic restoration in both cases.
• Timely differential diagnosis is essential when ICI-associated toxicity is suspected.
• Further large-scale studies are needed to determine optimal glucocorticoid dosing and treatment duration.

Clinical Implications

Healthcare providers should be vigilant for signs of myelosuppression in patients receiving ICI and chemotherapy. Immediate glucocorticoid treatment may be necessary to manage suspected immune-mediated myelosuppression effectively.

Conclusion

The findings underscore the need for awareness and prompt management of myelosuppression in patients undergoing combined ICI and chemotherapy. Further research is warranted to refine treatment protocols.

References

1. Frontiers in Immunology, 2026 -- Severe neuromyelitis optica spectrum disorder induced by pucotenlimab: a case report and literature review
2. Bone Marrow Transplantation, 2021 -- Management Strategies and Treatment Alternatives for Steroid-Refractory Chronic Graft-Versus-Host Disease
3. Journal of Neuro-Oncology, 2022 -- A Systematic Review of Immune-Related Aseptic Meningitis and Management Approaches for Immune Checkpoint Inhibitor Therapy
4. The ASCO Post, 2020 -- Do HIV Positivity and Autoimmune Disease Preclude Treatment With Checkpoint Inhibitors?
5. Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA - PubMed
6. Hematological toxicity of immune checkpoint inhibitors: a pharmacovigilance study - PMC
7. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events - PMC
8. Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA - PubMed
9. Hematological toxicity of immune checkpoint inhibitors: a pharmacovigilance study - PMC
10. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events - PMC